keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant and gastric cancer

keyword
https://www.readbyqxmd.com/read/28707042/validity-of-neoadjuvant-chemotherapy-with-docetaxel-cisplatin-and-s-1-for-resectable-locally-advanced-gastric-cancer
#1
Kinro Sasaki, Shinichi Onodera, Kichiro Otsuka, Hitoshi Satomura, Eigo Kurayama, Tsukasa Kubo, Masakazu Takahashi, Jun Ito, Masanobu Nakajima, Satoru Yamaguchi, Kazuhito Miyachi, Hiroyuki Kato
Gastrectomy with D2 lymphadenectomy plus postoperative chemotherapy is the standard treatment for resectable locally advanced gastric cancer in Japan. However, the prognosis of patients with serosa-positive tumors remains unsatisfactory because of peritoneal recurrence. This study aimed to investigate the validity of neoadjuvant therapy with docetaxel, cisplatin, and S-1 (DCS) in patients with locally advanced gastric cancer. Thirty patients with locally advanced gastric cancer underwent neoadjuvant DCS therapy at Dokkyo Medical University Hospital between June 2013 and October 2015...
August 2017: Medical Oncology
https://www.readbyqxmd.com/read/28697579/can-low-dose-ct-perfusion-imaging-accurately-assess-response-of-advanced-gastric-cancer-with-neoadjuvant-chemotherapy
#2
Zong-Qiong Sun, Gen Yan, Yu-Xi Ge, Jie Li, Lin-Fang Jin, Zhi-Hui Xie, Peng Zhao
PURPOSE: To explore the value of low-dose CT perfusion imaging (LDCTPI) technology and its perfusion parameters in assessing response of neoadjuvant chemotherapy (NAC) in patients with advanced gastric cancer (AGC). METHODS: Thirty patients with AGC were studied prospectively by LDCTPI to measure two parameters including blood flow (BF) and blood volume (BV) of tumor area before and after chemotherapy, respectively. All of the patients received two courses of NAC and surgical resection of gastric tumor within one week after chemotherapy, and then obtained the result of postoperative pathology response for chemotherapy...
July 7, 2017: Journal of X-ray Science and Technology
https://www.readbyqxmd.com/read/28687001/clinical-efficacy-of-neoadjuvant-chemotherapy-regimens-fleeox-vs-xelox-in-patients-with-initially-unresectable-advanced-gastric-cancer-a-propensity-score-analysis
#3
Yang Li, Jun Chen, Qi He, Xiang Ji, Xulin Wang, Chaogang Fan, Guoli Li
PURPOSE: This study was designed to assess the effectiveness of FLEEOX (5-Fu, leucovorin, etoposide, oxaliplatin, and epirubicin) compared with XELOX (capecitabine and oxaliplatin) as neoadjuvant chemotherapy (NAC) for initially unresectable advanced gastric cancer (AGC). METHODS: This study reviewed patients who underwent FLEEOX or XELOX for initially unresectable AGC. To reduce the bias in patient selection, we conducted propensity score match (PSM) with 1:1 ratio...
June 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28671728/clonality-analysis-of-synchronous-gastroesophageal-junction-carcinoma-and-distal-gastric-cancer-by-whole-exome-sequencing
#4
Xiaofang Xing, Shuqin Jia, Jianmin Wu, Qin Feng, Bin Dong, Bo Li, Yongning Jia, Fei Shan, Ying'ai Li, Yan Zhang, Ying Hu, Xiaodong Wang, Xiangtao Liu, Shiwei Yu, Lianhai Zhang, Zhaode Bu, Aiwen Wu, Ziyu Li, Jiafu Ji
Gastroesophageal junction (GEJ) carcinoma and distal gastric cancer (GC) have distinct epidemiology and clinical features and their relationship is uncertain. Synchronous multiple gastric cancers located mostly at proximal and distal sites provide rare specimens for investigating the comprehensive genomic relationships among these cancers in the context of identical genetic circumstances. Formalin-fixed, paraffin-embedded (FFPE) samples from 12 patients with synchronous GEJ carcinoma and distal GC were collected in this study...
July 3, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28671042/progress-in-the-treatment-of-advanced-gastric-cancer
#5
Zheyu Song, Yuanyu Wu, Jiebing Yang, Dingquan Yang, Xuedong Fang
Gastric cancer is one of the most common malignant tumors in the digestive system. Surgery is currently considered to be the only radical treatment. As surgical techniques improve and progress is made in traditional radiotherapy, chemotherapy, and the implementation of neoadjuvant therapy, the 5-year survival rate of early gastric cancer can reach >95%. However, the low rate of early diagnosis means that most patients have advanced-stage disease at diagnosis and so the best surgical window is missed. Therefore, the main treatment for advanced gastric cancer is the combination of neoadjuvant chemoradiotherapy, molecular-targeted therapy, and immunotherapy...
July 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28668863/phase-i-study-of-neoadjuvant-chemotherapy-with-capecitabine-and-oxaliplatin-for-locally-advanced-gastric-cancer
#6
Hironaga Satake, Masato Kondo, Motoko Mizumoto, Takeshi Kotake, Yoshihiro Okita, Takatsugu Ogata, Yukimasa Hatachi, Hisateru Yasui, Akira Miki, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
AIM: To determine the recommended dose of neoadjuvant chemotherapy of combined capecitabine and oxalipatin (G-XELOX) for locally advanced gastric cancer. PATIENTS AND METHODS: Patients received two cycles of neoadjuvant chemotherapy with oxaliplatin on day 1 and capecitabine (2,000 mg/m(2)/day, b.i.d.) on days 1-14, repeated every 3 weeks. They then underwent gastrectomy with curative D2/3 lymph-node dissection followed by adjuvant therapy with S-1 for 1 year. De-escalation of oxaliplatin dose was planned (starting at level 1, oxalipatin 130 mg/m(2))...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28643069/lessons-learned-from-a-phase-ii-clinical-trial-of-laparoscopic-hipec-for-gastric-cancer
#7
Brian Badgwell, Mariela Blum, Prajnan Das, Jeannelyn Estrella, Xuemei Wang, Keith Fournier, Richard Royal, Paul Mansfield, Jaffer Ajani
BACKGROUND: Over the last two decades, intraperitoneal chemotherapy has been found to have activity for select subgroups of patients with carcinomatosis from colon, ovarian, appendiceal, and recently, gastric origins. However, there is little data to support an aggressive surgical approach of cytoreduction (debulking) and hyperthermic intraperitoneal perfusion with chemotherapy (HIPEC) for patients with gastric cancer and positive cytology or carcinomatosis. The morbidity and mortality rates of cytoreduction and HIPEC, in combination with gastrectomy, are significant and the survival rates of this approach may not extend beyond that of treatment with systemic chemotherapy...
June 22, 2017: Surgical Endoscopy
https://www.readbyqxmd.com/read/28616743/the-long-term-survival-of-stage-iv-gastric-cancer-patients-with-conversion-therapy
#8
Kazuya Yamaguchi, Kazuhiro Yoshida, Toshiyuki Tanahashi, Takao Takahashi, Nobuhisa Matsuhashi, Yoshihiro Tanaka, Kazuaki Tanabe, Hideki Ohdan
PURPOSE: A retrospective study was performed to clarify the role of conversion therapy (surgery with a prospect of R0 resection performed in initially unresectable metastatic cancer that responded to the chemotherapy) in stage IV gastric cancer (GC). PATIENTS AND METHODS: We treated 259 stage IV GC patients with systemic chemotherapy at Gifu and Hiroshima University Hospitals between 2001-2013. Of these, 84 patients who were subsequently treated by surgery were classified into four categories according to our previously published classification of stage IV GC, and short- and long-term outcomes were analyzed...
June 14, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28611300/consistency-mapping-of-16-lymph-node-stations-in-gastric-cancer-by-ct-based-vessel-guided-delineation-of-255-patients
#9
Shuhang Xu, Lingling Feng, Yongming Chen, Ying Sun, Yao Lu, Shaomin Huang, Yang Fu, Rongqin Zheng, Yujing Zhang, Rong Zhang
In order to refine the location and metastasis-risk density of 16 lymph node stations of gastric cancer for neoadjuvant radiotherapy, we retrospectively reviewed the initial images and pathological reports of 255 gastric cancer patients with lymphatic metastasis. Metastatic lymph nodes identified in the initial computed tomography images were investigated by two radiologists with gastrointestinal specialty. A circle with a diameter of 5 mm was used to identify the central position of each metastatic lymph node, defined as the LNc (the central position of the lymph node)...
June 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/28599492/histological-evaluations-of-primary-lesions-are-independently-associated-with-prognosis-in-patients-with-gastric-cancer-who-receive-neoadjuvant-chemotherapy
#10
Tomomitsu Tahara, Tomoyuki Shibata, Masaaki Okubo, Dai Yoshida, Tomohiko Kawamura, Noriyuki Horiguchi, Takamitsu Ishizuka, Mitsuo Nagasaka, Yoshihito Nakagawa, Naoki Ohmiya
Neoadjuvant chemotherapy may improve outcomes for patients with locally advanced gastric cancer (GC). To explore useful predictive factors for the response of advanced GC to neoadjuvant chemotherapy, tumor responses were assessed using computed tomography (CT) with histological based criteria. A total of 78 patients with advanced GC undergoing neoadjuvant chemotherapy were included. CT-based response assessment was performed following 2 courses of treatment. Histological evaluation of resected specimens was also performed according to the Japanese classification of gastric carcinoma...
June 2017: Oncology Letters
https://www.readbyqxmd.com/read/28553122/peripheral-venous-blood-neutrophil-to-lymphocyte-ratio-predicts-survival-in-patients-with-advanced-gastric-cancer-treated-with-neoadjuvant-chemotherapy
#11
Li Chen, Yanjiao Zuo, Lihua Zhu, Yuxin Zhang, Sen Li, Fei Ma, Yu Han, Hongjiang Song, Yingwei Xue
BACKGROUND: Accurate and useful predictors of gastric carcinoma treated with neoadjuvant chemotherapy are lacking at present. We aim to explore the potential prognostic significance of the neutrophil-to-lymphocyte ratio (NLR) in advanced gastric cancer receiving S-1 plus oxaliplatin (SOX) or oxaliplatin and capecitabine (XELOX) regimen. METHODS: We enrolled 91 patients with advanced gastric cancer treated with neoadjuvant chemotherapy from August 2008 to September 2015...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28535156/phase-ii-study-of-neoadjuvant-imatinib-in-large-gastrointestinal-stromal-tumours-of-the-stomach
#12
Yukinori Kurokawa, Han-Kwang Yang, Haruhiko Cho, Min-Hee Ryu, Toru Masuzawa, Sook Ryun Park, Sohei Matsumoto, Hyuk-Joon Lee, Hiroshi Honda, Oh Kyoung Kwon, Takashi Ishikawa, Kyung Hee Lee, Kazuhito Nabeshima, Seong-Ho Kong, Toshio Shimokawa, Jeong-Hwan Yook, Yuichiro Doki, Seock-Ah Im, Seiichi Hirota, Seokyung Hahn, Toshirou Nishida, Yoon-Koo Kang
BACKGROUND: Gastrointestinal stromal tumours (GISTs) with high-risk features have poor prognosis even if adjuvant treatment is given. Neoadjuvant imatinib may increase the cure rate by shrinking large GISTs and preserve organ function. METHODS: We conducted an Asian multinational phase II study for patients with gastric GISTs ≥10 cm. Patients received neoadjuvant imatinib (400 mg/day) for 6-9 months. The primary end point was R0 resection rate. RESULTS: A total of 56 patients were enroled in this study...
June 27, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28529985/recent-trends-of-gastric-cancer-treatment-in-turkey
#13
REVIEW
Ali Guner
Gastric cancer is the fifth most common type of cancer and is the fourth most common death due to cancer in Turkey. Incidence and mortality rates are one of the highest among European countries. Despite the high rates, management of gastric cancer is still an issue of debate in Turkey and national guidelines have yet to be established. While the treatment plan following the diagnosis of gastric cancer is determined by a multidisciplinary meeting at high-volume centers, the plan in the majority of cases in Turkey is decided based on the decision of an individual physician...
2017: Translational Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28526077/the-optimal-extent-of-gastrectomy-for-middle-third-gastric-cancer-distal-subtotal-gastrectomy-is-superior-to-total-gastrectomy-in-short-term-effect-without-sacrificing-long-term-survival
#14
Xin Ji, Yan Yan, Zhao-De Bu, Zi-Yu Li, Ai-Wen Wu, Lian-Hai Zhang, Xiao-Jiang Wu, Xiang-Long Zong, Shuang-Xi Li, Fei Shan, Zi-Yu Jia, Jia-Fu Ji
BACKGROUND: The optimal extent of gastrectomy for middle-third gastric cancer remains controversial. In our study, the short-term effects and longer-term survival outcomes of distal subtotal gastrectomy and total gastrectomy are analysed to determine the optimal extent of gastrectomy for middle-third gastric cancer. METHODS: We retrospectively collect and analyse clinicopathologic data and follow-up outcomes from a prospectively collected database at the Peking University Cancer Hospital...
May 19, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28512415/neoadjuvant-chemotherapy-and-adjuvant-chemoradiation-therapy-in-the-treatment-of-resected-gastric-adenocarcinoma-a-case-series
#15
Christina Hadzitheodorou, Rebecca A Moss, Timothy J Kennedy, Salma K Jabbour
The treatment of gastric cancer requires a multimodal approach to decrease the risk of locoregional and distant recurrence. The optimal timing of chemotherapy, surgery, and radiation therapy continues to be explored in ongoing trials. In the United States, surgical resection is often followed by adjuvant chemoradiation therapy or by a combination of neoadjuvant and adjuvant chemotherapy. Here we report on 4 patients with resected gastric adenocarcinoma who were treated with a combination of these 2 approaches, receiving neoadjuvant chemotherapy followed by adjuvant chemoradiation therapy...
January 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28501087/the-role-of-radiotherapy-in-localized-esophageal-and-gastric-cancer
#16
REVIEW
John Ng, Percy Lee
Multimodality management has become a core treatment principle for locally advanced esophageal, gastroesophageal junction (GEJ), and gastric cancer. Radiotherapy serves an important role for optimizing patient outcomes. This article reviews the evolving role of radiotherapy in the multidisciplinary management of esophageal, GEJ, and gastric cancer, summarizing the results of recent clinical trials leading to contemporary accepted treatment approaches. A major theme is the evidence supporting the role of radiotherapy in combined modality management, particularly the trend toward its delivery in the neoadjuvant setting...
June 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/28486692/early-results-of-a-randomized-two-by-two-factorial-phase-ii-trial-comparing-neoadjuvant-chemotherapy-with-two-and-four-courses-of-cisplatin-s-1-and-docetaxel-cisplatin-s-1-as-neoadjuvant-chemotherapy-for-locally-advanced-gastric-cancer
#17
T Aoyama, K Nishikawa, K Fujitani, K Tanabe, S Ito, T Matsui, A Miki, H Nemoto, K Sakamaki, T Fukunaga, Y Kimura, N Hirabayashi, T Yoshikawa
Neoadjuvant chemotherapy (NAC) is a promising method of improving the survival of resectable gastric cancer. Cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) are both effective against metastatic gastric cancer. This report clarified the impact of these regimens on early endpoints, including the pathological responses, chemotherapy-related toxicities, and surgical results. Patients with M0 and either T4 or T3 in case of junctional cancer or schirrhous type received 2 or 4 courses of cisplatin (60 mg/m 2 at day 8)/S-1 (80 mg/m 2 for 21 days with 1 week rest) or docetaxel (40 mg/m 2 at day 1)/cisplatin (60 mg/m 2 at day 1)/S-1 (80 mg/m 2 for 14 days with 2 weeks rest) as neoadjuvant chemotherapy...
May 9, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28484222/in-silico-evaluation-of-dna-damage-inducible-transcript-4-gene-ddit4-as-prognostic-biomarker-in-several-malignancies
#18
Joseph A Pinto, Christian Rolfo, Luis E Raez, Alexandra Prado, Jhajaira M Araujo, Leny Bravo, Williams Fajardo, Zaida D Morante, Alfredo Aguilar, Silvia P Neciosup, Luis A Mas, Denisse Bretel, Justin M Balko, Henry L Gomez
DDIT4 gene encodes a protein whose main action is to inhibit mTOR under stress conditions whilst several in vitro studies indicate that its expression favors cancer progression. We have previously described that DDIT4 expression is an independent prognostic factor for tripe negative breast cancer resistant to neoadjuvant chemotherapy. We herein report that high DDIT4 expression is related to the outcome (recurrence-free survival, time to progression and overall survival) in several cancer types. We performed in silico analysis in online platforms, in pooled datasets from KM Plotter and meta-analysis of individual datasets from SurvExpress...
May 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28483410/neoadjuvant-chemotherapy-survival-benefit-in-gastric-cancer
#19
Manjulika Das
No abstract text is available yet for this article.
June 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28475005/impact-of-the-immune-cell-population-in-peripheral-blood-on-response-and-survival-in-patients-receiving-neoadjuvant-chemotherapy-for-advanced-gastric-cancer
#20
Qi He, Guoli Li, Xiang Ji, Long Ma, Xulin Wang, Yang Li, Chaogang Fan
We aimed to investigate the prognostic value of the immune cells population in peripheral blood from patients with advanced gastric cancer treated with neoadjuvant chemotherapy. A total of 105 patients with advanced gastric cancer were evaluated in this study. Blood samples were collected before and 1 week after the last dose of chemotherapy. The percentage of CD3+, CD3+CD4+, CD3+CD8+, and CD4+CD25+Foxp3+ T cells was assessed using flow cytometry analysis. The relationship between T cell subsets and clinical outcome was evaluated...
May 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
keyword
keyword
110856
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"